|The CD73 n/a (Catalog #MBS584066) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The CD73, Human, mAb 4G4 reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s CD73 can be used in a range of immunoassay formats including, but not limited to, F, Flow Cytometry (FC/FACS), FS, Immunoflurescence (IF), Immunoprecipitation (IP), Western Blot (WB).
Application Notes: F:- Tissue sections were fixed in acetone.- As positive control anti-CD31 was used and as negative control an isotype antibody (Ref.5).
Application Use: For immunohistology, and flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user\'s experimental setting. Researchers should empirically determine the suitability of the CD73 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Product Description: The monoclonal antibody 4G4 recognizes both membrane bound and soluble human CD73, also known as ecto-5-nucleotidase. CD73 is a 70-kDa GPI-anchored cell surface molecule and belongs to the 5-nucleosidase family. CD73 is useful as marker for lymphocyte differentiation. It is abundantly expressed on the vascular endothelium and at a low level on certain subpopulations of human lymphocytes. Like many glycosyl-phosphatidylinositol (GPI)-anchored molecules, it transmits potent activation signals in T cells when ligated by antibodies. CD73 hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Ecto-5-nucleotidase activity is an important mediator of the antiinflammatory effect by converting extracellular AMP into a potent anti-inflammatory substance adenosine. CD73 has been shown to function as a co-stimulatory molecule in human T cells and to have a role in regulating lymphocyte adhesion. Triggering of CD73 on the surface of lymphocytes, but not on endothelial cells, results in the shedding of the CD73 and increased adhesion of lymphocytes to endothelium via LFA-1 clustering. Furthermore, CD73 has been implicated to mediate homing of skin-infiltrating lymphocytes in vivo.
In B-cell chronic lymphocytic leukemia the expression of CD73 is decreased. Besides this, CD73 activity has been implicated as sensitive and useful indicator for mild zinc deficiency. The monoclonal antibody 4G4 causes a reduction in CD73 expression on lymphocytes, reduces enzyme activity, and inhibits the binding of lymphocytes to endothelial cells.
Immunogen: Inflamed synovial stroma from rheumatoid arthitis patients. Positive Control: HUVEC and fresh lymphocytes. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD73 are readily searchable from our website. Different antibodies against the same target such as CD73 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.